多发性骨髓瘤微小残留病检测及其临床应用

doi:10.16150/j.1671-2870.2017.05.005

摘要/Abstract

关键词: 多发性骨髓瘤, 微小残留病, 流式细胞术, 分子生物学, 正电子发射型计算机断层显像

中图分类号:

R551.3

李晓帆, 王少元. 多发性骨髓瘤微小残留病检测及其临床应用[J]. 诊断学理论与实践, 2017, 16(05): 472-476.

[1] Smith D, Yong K.Advances in understanding prognosis in myeloma[J]. Br J Haematol,2016,175(3):367-380.
[2] 黎建云, 徐岚, 李军民, 等. PAD及VAD样-T方案治疗多发性骨髓瘤126例效果比较[J]. 白血病·淋巴瘤,2016,25(9):535-538.
[3] 肖超, 常春康. 骨髓瘤骨病的病理机制进展与治疗[J]. 诊断学理论与实践,2015,14(4):375-380.
[4] Rajkumar SV.Myeloma today: Disease definitions and treatment advances[J]. Am J Hematol,2016,91(1):90-100.
[5] Palumbo A, Rajkumar SV, San Miguel JF, et al.International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation[J]. J Clin Oncol,2014,32(6):587-600.
[6] Lahuerta JJ, Paiva B, Vidriales MB, et al.Depth of response in multiple myeloma: A pooled analysis of Three PETHEMA/GEM Clinical Trials[J]. J Clin Oncol,2017, 35(25):2900-2910.
[7] Korde N, Roschewski M, Zingone A, et al.Treatment with Carfilzomib-Lenalidomide-Dexamethasone with lenalidomide extension in patients With smoldering or newly diagnosed multiple myeloma[J]. JAMA Oncol,2015,1(6):746-754.
[8] Mateos MV, Martínez-López J, Hernández MT, et al.Sequential vs alternating administration of VMP and Rd in elderly patients with newly diagnosed MM[J]. Blood,2016,127(4):420-425.
[9] Jakubowiak AJ, Dytfeld D, Griffith KA, et al.A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma[J]. Blood,2012,120(9):1801-1809.
[10] Dytfeld D, Jasielec J, Griffith KA, et al.Carfilzomib, lenalidomide, and low-dose dexamethasone in elderly patients with newly diagnosed multiple myeloma[J]. Haematologica,2014,99(9):e162-e164.
[11] Innao V, Allegra A, Russo S, et al. Standardisation of minimal residual disease in multiple myeloma[J/OL]. Eur J Cancer Care (Engl),2017-07-03[2017-08-05].https://www.ncbi.nlm.nih.gov/pubmed/28671297.
[12] Gay F, Larocca A, Wijermans P, et al.Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients[J]. Blood,2011,117(11):3025-3031.
[13] Rajkumar SV.Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management[J]. Am J Hematol,2016,91(7):719-734.
[14] Landgren O, Owen RG.Better therapy requires better response evaluation: Paving the way for minimal residual disease testing for every myeloma patient[J]. Cytometry B Clin Cytom,2016,90(1):14-20.
[15] Martinez-Lopez J, Lahuerta JJ, Pepin F, et al.Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma[J]. Blood,2014, 123(20):3073-3079.
[16] Rawstron AC, Gregory WM, de Tute RM, et al. Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction[J]. Blood,2015,125(12):1932-1935.
[17] Paiva B, Vidriales MB, Cerveró J, et al.Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation[J]. Blood,2008,112(10):4017-4023.
[18] Kumar S, Paiva B, Anderson KC, et al.International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma[J]. Lancet Oncol,2016,17(8):e328-e346.
[19] Behdad A, Ross CW, Jacques J, et al.Utility of nine-color, 11-parameter flow cytometry for detection of plasma cell neoplasms: a comparison with bone marrow morphologic findings and concurrent M-protein studies in serum and urine[J]. Am J Clin Pathol,2014,142(3):398-410.
[20] Paiva B, Martinez-Lopez J, Vidriales MB, et al.Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma[J]. J Clin Oncol,2011,29(12):1627-1633.
[21] Gonsalves WI, Rajkumar SV, Dispenzieri A, et al.Quantification of circulating clonal plasma cells via multiparametric flow cytometry identifies patients with smoldering multiple myeloma at high risk of progression[J]. Leukemia,2017,31(1):130-135.
[22] Gonsalves WI, Morice WG, Rajkumar V, et al.Quantification of clonal circulating plasma cells in relapsed multiple myeloma[J]. Br J Haematol,2014,167(4):500-505.
[23] Flores-Montero J, Sanoja-Flores L, Paiva B, et al. Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma[J/OL]. Leukemia,2017-03-10[2017-08-05].https://www.ncbi.nlm.nih.gov/pubmed/28104919.
[24] Puig N, Sarasquete ME, Balanzategui A, et al.Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry[J]. Leukemia,2014,28(2):391-397.
[25] Drandi D, Kubiczkova-Besse L, Ferrero S, et al.Minimal residual disease detection by droplet digital PCR in multiple myeloma, mantle cell lymphoma, and follicular lymphoma: A comparison with real-time PCR[J]. J Mol Diagn,2015,17(6):652-660.
[26] Sata H, Shibayama H, Maeda I, et al.Quantitative polymerase chain reaction analysis with allele-specific oligonucleotide primers for individual IgH VDJ regions to evaluate tumor burden in myeloma patients[J]. Experimental hematology,2015,43(5):374-381.
[27] Ladetto M, Brüggemann M, Monitillo L, et al.Next-gene-ration sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders[J]. Leukemia,2014,28(6):1299-1307.
[28] Usmani SZ, Mitchell A, Waheed S, et al.Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3[J]. Blood,2013,121(10):1819-1823.
[29] Zamagni E, Nanni C, Mancuso K, et al.PET/CT Improves the Definition of Complete Response and Allows to Detect Otherwise Unidentifiable Skeletal Progression in Multiple Myeloma[J]. Clin Cancer Res,2015,21(19):4384-4390.
[30] Lapa C, Knop S, Schreder M, et al.11C-Methionine-PET in multiple myeloma: Correlation with clinical parameters and bone marrow involvement[J]. Theranostics,2016,6(2):254-261.
[31] Philipp-Abbrederis K, Herrmann K, Knop S, et al.In vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma[J]. EMBO Mol Med,2015,7(4):477-487.
[32] Dimopoulos MA, Hillengass J, Usmani S, et al.Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement[J]. J Clin Oncol,2015,33(6):657-664.
[33] Barnidge DR, Dasari S, Botz CM, et al.Using mass spectrometry to monitor monoclonal immunoglobulins in patients with a monoclonal gammopathy[J]. J Proteome Res,2014,13(3):1419-1427.
[34] Barnidge DR, Tschumper RC, Theis JD, et al.Monitoring M-proteins in patients with multiple myeloma using heavy-chain variable region clonotypic peptides and LC-MS/MS[J]. J Proteome Res,2014,13(4):1905-1910.
[35] Bergen HR 3rd, Dasari S, Dispenzieri A, et al. Clonoty-pic light chain peptides identified for monitoring minimal residual disease in multiple myeloma without bone marrow aspiration[J]. Clin Chem,2016,62(1):243-251.
[36] Martínez-López J, Paiva B, López-Anglada L, et al.Critical analysis of the stringent complete response in multiple myeloma: contribution of sFLC and bone marrow clonality[J]. Blood,2015,126(7):858-862.
[37] Munshi NC, Avet-Loiseau H, Rawstron AC, et al.Associa-tion of minimal residual disease with superior survival outcomes in patients with multiple myeloma: A meta-analysis[J]. JAMA Oncol,2017,3(1):28-35.
[38] Paiva B, Chandia M, Puig N, et al.The prognostic value of multiparameter flow cytometry minimal residual disease assessment in relapsed multiple myeloma[J]. Haematologica,2015,100(2):e53-e55.

多发性骨髓瘤微小残留病检测及其临床应用

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	陈曦, 杜鹃. 多发性骨髓瘤预后风险的精准评估[J]. 诊断学理论与实践, 2021, 20(06): 522-528.
[2]	寇明坤, 徐娜娜, 石静云, 吴涛. 达妥木单抗在多发性骨髓瘤一线治疗中的应用进展[J]. 诊断学理论与实践, 2021, 20(06): 588-591.
[3]	赵建治, 糜坚青. 多发性骨髓瘤相关生物标志物的研究进展[J]. 诊断学理论与实践, 2021, 20(05): 507-511.
[4]	范春丽, 吴涛, 薛锋, 胡文雪, 王存邦, 白海. MUM1/IRF4阳性弥漫大B细胞淋巴瘤一例治疗报告并文献复习[J]. 诊断学理论与实践, 2021, 20(04): 399-400.
[5]	彭真萍, 项喜喜, 张苏江, 李佳明. 以类白血病反应为首发表现的慢性中性粒细胞白血病二例并文献复习[J]. 诊断学理论与实践, 2020, 19(02): 122-128.
[6]	来小音, 孙家兰, 胡荣郭, 杨雪莲, 吴国炉, 李龙宣, 卜碧涛. T淋巴细胞亚群失衡与全身型重症肌无力临床症状加重及缓解的相关性研究[J]. 诊断学理论与实践, 2019, 18(2): 199-203.
[7]	陆弘逾, 曹亚峰, 顾俊, 王静, 陈梅, 宋陆茜. 神经电生理检查对多发性骨髓瘤患者硼替佐米治疗相关周围神经病的预测及诊断意义[J]. 诊断学理论与实践, 2019, 18(06): 640-644.
[8]	梁璆荔, 姜晓星, 陈宁, 吴洁敏, 李莉, 刘湘帆, 倪培华. 基于团队学习的教学法在分子生物学检验技术实验教学中的探索及应用[J]. 诊断学理论与实践, 2019, 18(03): 371-373.
[9]	侯健, 刘进. 2017年欧洲肿瘤内科学会多发性骨髓瘤的指南更新解读[J]. 诊断学理论与实践, 2017, 16(05): 455-459.
[10]	汪萍, 沈立松, 张冬青. 多发性骨髓瘤及相关疾病的实验室诊断认识[J]. 诊断学理论与实践, 2017, 16(05): 477-483.
[11]	糜坚青, 金诗炜. 多发性骨髓瘤细胞分子遗传学异常与预后分层、治疗[J]. 诊断学理论与实践, 2017, 16(05): 460-463.
[12]	曹亚峰, 王静, 顾俊, 陆弘逾, 许杰, 刘元坊, 王焰, 王瑾, 陈钰, 陈玉宝, 李佳明, 郝杰, 糜坚青, 陈梅. 以硼替佐米为基础的联合方案治疗114例初诊多发性骨髓瘤患者的周围神经病变分析[J]. 诊断学理论与实践, 2017, 16(05): 492-497.
[13]	王建中. 流式细胞术诊断急性白血病微小残留病：当前主要的技术问题和对策[J]. 诊断学理论与实践, 2017, 16(01): 7-11.
[14]	陈冰, 眭竫旎. 急性髓系白血病微小残留病监测方式的展望[J]. 诊断学理论与实践, 2017, 16(01): 17-26.
[15]	王敏敏, 颜敏超, 郭晓珺. 硼替佐米和沙利度胺治疗多发性骨髓瘤致相关周围神经病变机制[J]. 诊断学理论与实践, 2016, 15(06): 629-631.